The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
BACKGROUND: Familial hypercholesterolemia is characterized by an elevated level of low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Monoclonal antibodies directed against proprotein convertase subtilisin-kexin type 9 (PCSK9) have been shown to reduce LDL cholesterol levels by more than 50% but require administration every 2 to 4 weeks. In a phase 2 trial, a twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial hypercholesterolemia. METHODS: In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections of inclisiran sodium (at a dose of 300 mg) or matching placebo on days 1, 90, 270, and 450. The two primary end points were the percent change from baseline in the LDL cholesterol level on day 510 and the time-adjusted percent change from baseline in the LDL cholesterol level between day 90 and day 540. RESULTS: The median age of the patients was 56 years, and 47% were men; the mean baseline level of LDL cholesterol was 153 mg per deciliter. At day 510, the percent change in the LDL cholesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisiran group and an increase of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 percentage points (95% CI, -53.5 to -42.3; P<0.001). The time-averaged percent change in the LDL cholesterol level between day 90 and day 540 was a reduction of 38.1% (95% CI, -41.1 to -35.1) in the inclisiran group and an increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 percentage points (95% CI, -48.5 to -40.1; P<0.001). There were robust reductions in LDL cholesterol levels in all genotypes of familial hypercholesterolemia. Adverse events and serious adverse events were similar in the two groups. CONCLUSIONS: Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran lowered LDL-C by 47.9% in the 482 HeFH patients enrolled in ORION-9 at Day 510 [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study by Raal et al. focused on HeFH patients displayed an outlier position in the lower left quadrant of the funnel because it had both a small effect size and a wide standard error [39].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results were confirmed in the phase 3 ORION-9 trial which showed a − 48% LDL-C reduction of inclisiran relative to placebo among 482 patients with HeFH [138].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran improved multiple lipid parameters including non-HDL-C, apoB, triglycerides and lipoprotein(a) in addition to LDL-C which makes it beneficial for complete lipid management [39, 43, 49].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Heart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citationSequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationTherapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 820
A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia
Brandts, J., Dharmayat, K., Vallejo‐Vaz, A. J., Sharabiani, M. T. A., Jones, R., Kastelein, J. J. P., Raal, F. J., & Ray, K. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.042 · Cited by 30
Self-citationBiotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
Cunha, D. B. E., Frederico, A. B. T., Azamor, T., Melgaço, J. G., Neves, P., Bom, A., Tilli, T. M., & Missailidis, S. (2022) · Pharmaceuticals · doi:10.3390/ph15050575 · Cited by 32
Effects of Lipoproteins on Metabolic Health
Albitar, O., D’Souza, C. M., & Adeghate, E. A. (2024) · Nutrients · doi:10.3390/nu16132156 · Cited by 41
Bchetnia, M., Bouchard, L., Mathieu, J., Campeau, P. M., Morin, C., Brisson, D., Laberge, A., Vézina, H., Gaudet, D., & Laprise, C. (2021) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2021-107809 · Cited by 40
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 32
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
Samuel, E., Watford, M., Egolum, U. O., Ombengi, D., Ling, H., & Cates, D. W. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221105169 · Cited by 30
Luo, M., Liu, Y., Xu, X., Liu, K., Shen, C., Hu, H., He, Z., & Wu, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1158274 · Cited by 29
Dron, J. S., Patel, A. P., Zhang, Y., Jurgens, S. J., Maamari, D. J., Wang, M., Boerwinkle, E., Morrison, A. C., de Vries, P. S., Fornage, M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2022.5271 · Cited by 30
Kim, M. S., Song, M., Kim, B., Shim, I., Kim, D. S., Natarajan, P., Do, R., & Won, H. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101112 · Cited by 31
Linthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 29
In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial
Wan, P., Tang, S., Yang, T., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., Liu, Y., et al. (2025) · Nature Medicine · doi:10.1016/j.atherosclerosis.2025.119507 · Cited by 41
Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis
Li, J., Du, H., Wang, Y., Aertgeerts, B., Guyatt, G. H., Hao, Q., Shen, Y., Li, L., Su, N., Delvaux, N., et al. (2022) · Heart · doi:10.1136/heartjnl-2021-320556 · Cited by 29
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi‐Borojeni, A. A., Banach, M., Ruscica, M., & Sahebkar, A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2132229 · Cited by 28
Leiter, L. A., Raal, F. J., Schwartz, G. G., Koenig, W., Ray, K. K., Landmesser, U., Han, J., Conde, L. G., & Wright, R. S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15650 · Cited by 27
Self-citationZac‐Varghese, S., Mark, P. B., Bain, S. C., Banerjee, D., Chowdhury, T. A., Dasgupta, I., De, P., Fogarty, D. G., Frankel, A., Goldet, G., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03664-1 · Cited by 26
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 29
Self-citationThe Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 30
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 26
Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
Yang, C., Wu, Y., Qian, J., & Li, J. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2412373 · Cited by 27
Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15
Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64454 · Cited by 26
β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis
Ji, W., Zhang, Y., Shao, W., Kankala, R. K., & Chen, A. (2024) · Regenerative Biomaterials · doi:10.1093/rb/rbae071 · Cited by 26
Mansfield, B. S., Mohamed, F., Larouche, M., & Raal, F. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144160 · Cited by 28
Self-citationMauriello, A., Correra, A., Maratea, A. C., Caturano, A., Liccardo, B., Perrone, M. A., Giordano, A., Nigro, G., D’Andrea, A., & Russo, V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051652 · Cited by 29
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 26
Xu, M., Zhu, X., Wu, J., Zhang, Y., Zhao, D., Wang, X., Ding, Y., Cao, Y., Li, C., Hu, W. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02208-w · Cited by 27
Burnett, H. F., Fahrbach, K. R., Cichewicz, A. B., Jindal, R., Tarpey, J., Durand, A., Domenico, M. D., Reichelt, A., & Viljoen, A. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2049164 · Cited by 32
Inclisiran: How Widely and When Should We Use It?
Pirillo, A., & Catapano, A. L. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01056-0 · Cited by 27
Lipoprotein(a)—60 Years Later—What Do We Know?
Pasławska, A., & Tomasik, P. (2023) · Cells · doi:10.3390/cells12202472 · Cited by 31
Drug development advances in human genetics‐based targets
Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024) · MedComm · doi:10.1002/mco2.481 · Cited by 26
Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD
Taub, P. R., Gutierrez, A., Wewers, D., Garcia Cantu, E., Cao, H., Deck, C., Lesogor, A., Ott, D., Mena-Madrazo, J., Zang, X., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.04.049 · Cited by 25
Self-citationEffects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease
Wright, R. S., Ray, K. K., Landmesser, U., Koenig, W., Raal, F. J., Leiter, L. A., Conde, L. G., Han, J., & Schwartz, G. G. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.025 · Cited by 25
Self-citationHomozygous Familial Hypercholesterolemia Treatment: New Developments
Blom, D. J., Marais, A. D., & Raal, F. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01269-5 · Cited by 29
Self-citationGogate, A., Belcourt, J., Shah, M., Wang, A., Frankel, A., Kolmel, H., Chalon, M., Stephen, P., Kolli, A., Tawfik, S. M., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000815 · Cited by 27
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
Clinical Implications and Outcomes of the Orion Phase Iii Trials
Brandts, J., & Ray, K. K. (2020) · Future Cardiology · doi:10.2217/fca-2020-0150 · Cited by 30
Self-citationEmerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 28
Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
Morotti, A., Barale, C., Melchionda, E., & Russo, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911446 · Cited by 25
Asbeutah, A. A., Asbeutah, S. A., & Abu-Assi, M. A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.05.024 · Cited by 24
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Current Approaches to Epigenetic Therapy
Griazeva, E. D., Fedoseeva, D. M., Radion, E. I., Ershov, P. V., Meshkov, I. O., Semyanihina, A. V., Makarova, A. S., Makarov, V. V., Yudin, V. S., Keskinov, A. A., et al. (2023) · Epigenomes · doi:10.3390/epigenomes7040023 · Cited by 23
Wiegman, A., Peterson, A. L. H., Hegele, R. A., Bruckert, É., Schweizer, A., Lesogor, A., Wang, Y., & Defesche, J. C. (2025) · Circulation · doi:10.1161/circulationaha.124.073233 · Cited by 23
Lokras, A. G., Thakur, A., Wadhwa, A., Thanki, K., Franzyk, H., & Foged, C. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.601155 · Cited by 24
Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
Rogula, S., Błażejowska, E., Gąsecka, A., Szarpak, Ł., Jaguszewski, M. J., Mazurek, T., & Filipiak, K. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112467 · Cited by 25
Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
Hindi, N. N., Alenbawi, J., & Nemer, G. M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090877 · Cited by 23
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 35
Chiesa, G., Zenti, M. G., Baragetti, A., Barbagallo, C. M., Borghi, C., Colivicchi, F., Maggioni, A. P., Noto, D., Pirro, M., Rivellese, A. A., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.019 · Cited by 24
Sarzani, R., Spannella, F., Pentima, C. D., Giulietti, F., Landolfo, M., & Allevi, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010328 · Cited by 25
Mikami, A., Erande, N. D., Matsuda, S., Kel’in, A. V., Woods, L. B., Chickering, T., Pallan, P. S., Schlegel, M. K., Zlatev, I., Egli, M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa750 · Cited by 24
Krittanawong, C., Khawaja, M., Rosenson, R. S., Amos, C. I., Nambi, V., Lavie, C. J., & Virani, S. S. (2021) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2021.101043 · Cited by 21
Inclisiran: A New Pharmacological Approach for Hypercholesterolemia
Fusco, S. A. D., Maggioni, A. P., Bernelli, C., Perone, F., Marzo, V. D., Conte, E., Musella, F., Uccello, G., Luca, L. D., Gabrielli, D., et al. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2311375 · Cited by 24
Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
Dec, A., Niemiec, A., Wojciechowska, E., Maligłówka, M., Bułdak, Ł., Bołdys, A., & Okopień, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076858 · Cited by 22
Wołowiec, A., Wołowiec, Ł., Grześk, G., Jaśniak, A., Osiak, J., Husejko, J., & Kozakiewicz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813723 · Cited by 23
PCSK9-directed therapies: an update
Katzmann, J. L., & Laufs, U. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000919 · Cited by 22
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
Newman, C. B., & Tobert, J. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac708 · Cited by 20
Angoulvant, D., Granjeon-Noriot, S., Amarenco, P., Bastien, A., Béchet, E., Boccara, F., Boissel, J., Cariou, B., Courcelles, E., Diatchenko, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae254 · Cited by 26
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 21
Maraganore, J. M. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01304-3 · Cited by 21
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 22
Updates in Small Interfering RNA for the Treatment of Dyslipidemias
Carugo, S., Sirtori, C. R., Gelpi, G., Corsini, A., Tokgözoğlu, L. S., & Ruscica, M. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01156-5 · Cited by 22
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Pęczek, P., Leśniewski, M., Mazurek, T., Szarpak, Ł., Filipiak, K. J., & Gąsecka, A. (2021) · Life · doi:10.3390/life11060466 · Cited by 21
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials
Harbi, M. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1449712 · Cited by 21
Advances with lipid-lowering drugs for pediatric patients with familial hypercholesterolemia
Ferrari, F., Martins, V. M., Rocha, V. Z., & Santos, R. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1832991 · Cited by 20
Galactionova, K., Salari, P., Mattli, R., Rachamin, Y., Meier, R., & Schwenkglenks, M. M. (2022) · PharmacoEconomics · doi:10.1007/s40273-022-01152-8 · Cited by 20
The Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 21
Köenig, W., Ray, K. K., Landmesser, U., Leiter, L. A., Schwartz, G. G., Wright, R. S., Conde, L. G., Han, J., & Raal, F. J. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100503 · Cited by 21
Self-citationRNA nanomedicine in liver diseases
Bakrania, A. K., Mo, Y., Zheng, G., & Bhat, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000606 · Cited by 21
Poller, W. C., Sahoo, S., Hajjar, R. J., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 21
Akabane‐Nakata, M., Erande, N. D., Kumar, P., Degaonkar, R., Gilbert, J. A., Qin, J., Mendez, M., Woods, L. B., Jiang, Y., Janas, M. M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab050 · Cited by 20
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 22
Sawhney, J. P. S., & Madan, K. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.12.002 · Cited by 19
Gene therapy for polygenic or complex diseases
Wu, T., Hu, Y., & Tang, L. V. (2024) · Biomarker Research · doi:10.1186/s40364-024-00618-5 · Cited by 24
Dose-Dependent Nuclear Delivery and Transcriptional Repression with a Cell-Penetrant MeCP2
Zhang, X., Cattoglio, C., Zoltek, M., Vetralla, C., Mozumdar, D., & Schepartz, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01226 · Cited by 19
New Insights into Pathophysiology and New Risk Factors for ACS
Nardin, M., Verdoia, M., Laera, N., Cao, D., & Luca, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082883 · Cited by 21
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 19
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
Mohamed, F., Mansfield, B. S., & Raal, F. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155082 · Cited by 20
Self-citationFularski, P., Hajdys, J., Majchrowicz, G., Stabrawa, M., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031637 · Cited by 22
Naoum, I., Saliba, W., Aker, A., & Zafrir, B. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.05.003 · Cited by 19
Low cholesterol states: clinical implications and management
Gill, P. K., & Hegele, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204932 · Cited by 19
Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes
Rendell, M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1958779 · Cited by 18
Biologics and cardiac disease: challenges and opportunities
Ciucci, G., Colliva, A., Vuerich, R., Pompilio, G., & Zacchigna, S. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.06.001 · Cited by 18
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
Bell, A. S., Rosoff, D. B., Mavromatis, L. A., Jung, J., Wagner, J., & Lohoff, F. W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026122 · Cited by 19
Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review
Ardiana, M., Fadila, A. N., Zuhra, Z., Kusuma, N. M., Rurus, M. E. S. E., & Oceandy, D. (2023) · Non-coding RNA Research · doi:10.1016/j.ncrna.2023.06.002 · Cited by 18
New Biological Therapies for Low-Density Lipoprotein Cholesterol
Gill, P. K., & Hegele, R. A. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.08.003 · Cited by 18
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 18
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 19
Tandirerung, F. J. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01783-5 · Cited by 18
The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia
Ghazimoradi, M. H., Karimpour-Fard, N., & Babashah, S. (2023) · Genes · doi:10.3390/genes14010131 · Cited by 17
Zhou, Z., Zhang, W., Burgner, D. P., Tonkin, A. M., Zhu, C., Sun, C., Magnussen, C. G., Ernst, M. E., Breslin, M. C., Nicholls, S. J., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.02.025 · Cited by 18
Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment
Li, C., Pan, Y., Zhang, R., Huang, Z., Li, D., Han, Y., Larkin, C. T., Rao, V., Sun, X., & Kelly, T. N. (2023) · Circulation Research · doi:10.1161/circresaha.123.321999 · Cited by 18
siRNAs—A New Class of Medicines
Khvorova, A. (2023) · JAMA · doi:10.1001/jama.2023.4570 · Cited by 17
Tarugi, P., Bertolini, S., Calandra, S., Arca, M., Angelico, F., Casula, M., Cefalu, A. B., D’Erasmo, L., Fortunato, G., Filardi, P. P., et al. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.05.002 · Cited by 18
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
Banach, M., Kaźmierczak, J., Mitkowski, P. P., Wita, K., Broncel, M., Gąsior, M., Gierlotka, M. J., Gil, R. J., Jankowski, P., Niewada, M., et al. (2022) · Archives of Medical Science · doi:10.5114/aoms/147435 · Cited by 17
Kliuchnikov, E., Maksudov, F., Zuber, J., Hyde, S., Castoreno, A. B., Waldron, S., Schlegel, M. K., Marx, K. A., Maier, M. A., & Barsegov, V. A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102415 · Cited by 17
PCSK9 in T-cell function and the immune response
Wang, Y., Fang, X., Liu, J., Lv, X., Lu, K., Lu, Y., & Jiang, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00712-8 · Cited by 17
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Metadata
- Authors
- Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., & Kastelein, J. J. P.
- Affiliations
- University of the Witwatersrand (ZA)
- Medpace (United States) (US)
- From the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.); the Medicines Company, Zurich, Switzerland (D.K.); the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London (K.K.R.); Medpace Reference Laboratories, Cincinnati (T.T.); Deutsches Herzzentrum München, Technische Universität München, and German Center for Cardiovascular Research, Munich Heart Alliance, Munich (W.K.), and the...
- Mayo Clinic (US)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1520-1530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3011005820
- Semantic Scholar
- cd7f15bcb062953bf710c34645a08f7b4818c4d9
- Cited by
- 818
- References
- 52
- Citations by year
- 2026: 88 · 2025: 126 · 2024: 142 · 2023: 154 · 2022: 140 · 2021: 111 · 2020: 56
- FWCI
- 105.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, heterozygous familial hypercholesterolemia, PCSK9 inhibition, siRNA, LDL cholesterol lowering, atherosclerotic cardiovascular disease prevention, hypercholesterolemia treatment, lipid-lowering therapy, PCSK9 monoclonal antibodies
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Hyperlipoproteinemia Type II, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Treatment Outcome, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
